Onkologie. 2010:4(1):51-52
Erlotinib in the treatment of metastatic pancreatic carcinoma - a single-center experience
- 1 Oddělení klinické onkologie, Nemocnice Na Homolce, Praha
- 2 Klinika transplantační chirurgie IKEM, Praha
Pancreatic carcinoma has the poorest overall survival (OS) rate of any major cancer. The typical median OS for resectable disease is 12–22
months; for locally advanced 9–14 months; and for metastatic up to 8 months. Since 1997, when gemcitabin became the standard treatment
in metastatic settings, only insignificant progress has been seen. The combination of gemcitabin with targeted therapy, a new modality
in cancer treatment, has shown great potential.But the targeting of vascular endothelial growth factor (VEGFR) and epidermal growth
factor receptor I (EGFR/HER1) with monoclonal antibodies has been a failure. Erlotinib (Tarceva®) is an orally active, potent, selective
inhibitor of the EGFR/HER1 tyrosine kinase, which has been the first to show a survival benefit for patients with metastatic pancreatic
carcinoma. Our single-center experience has confirmed its tolerability, safety, and efficacy.
Keywords: pancreatic cancer, gemcitabin, erlotinib
Published: March 1, 2010 Show citation
References
- Vagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-594.
Go to original source... 
Go to PubMed... - Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27: 324-329. Go to original source... Go to PubMed...
- Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15. Go to original source... Go to PubMed...
- Michalski CW, Kleeff J, Wente MN, et al. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br. J. Surg 2007; 94: 265-273. Go to original source... Go to PubMed...
- Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413. Go to original source... Go to PubMed...
- Fja¨llskog MLH, Lejonklou MH, O¨ berg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469-1473.
- Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003; 11: 305-309. Go to original source...
- Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 2004; 54(suppl 1): S69-S77. Go to original source... Go to PubMed...
- Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29: E1-E8. Go to original source... Go to PubMed...
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 2007; 25: 1960-1966. Go to original source... Go to PubMed...